NASDAQ:AKRO - Akero Therapeutics Stock Price, News & Analysis

$19.04
-1.16 (-5.74 %)
(As of 09/17/2019 06:40 AM ET)
Today's Range
$18.37
Now: $19.04
$20.63
50-Day Range
$19.51
MA: $25.91
$29.60
52-Week Range
$16.06
Now: $19.04
$30.30
Volume138,800 shs
Average Volume90,212 shs
Market Capitalization$543.78 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKRO
CUSIPN/A
CIKN/A
Phone650-487-6488

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees8
Market Cap$543.78 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive AKRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.


Akero Therapeutics (NASDAQ:AKRO) Frequently Asked Questions

What is Akero Therapeutics' stock symbol?

Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics (NASDAQ:AKRO) announced its quarterly earnings results on Monday, August, 12th. The company reported ($2.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $1.85. View Akero Therapeutics' Earnings History.

When is Akero Therapeutics' next earnings date?

Akero Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Akero Therapeutics.

What price target have analysts set for AKRO?

4 analysts have issued 12 month price objectives for Akero Therapeutics' shares. Their forecasts range from $28.00 to $35.00. On average, they anticipate Akero Therapeutics' stock price to reach $31.25 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price. View Analyst Price Targets for Akero Therapeutics.

What is the consensus analysts' recommendation for Akero Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akero Therapeutics.

Has Akero Therapeutics been receiving favorable news coverage?

News coverage about AKRO stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Akero Therapeutics earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Akero Therapeutics.

Who are some of Akero Therapeutics' key competitors?

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Cronos Group (CRON), Immunomedics (IMMU), Teck Resources (TECK), Ability (ABIL), Axon Enterprise (AAXN), American Airlines Group (AAL), Westminster Group (WSG), Sanne Group (SNN), Rio Tinto (RIO) and India Capital Growth Fund (IGC).

Who are Akero Therapeutics' key executives?

Akero Therapeutics' management team includes the folowing people:
  • Dr. Andrew Cheng, Pres, Chief Exec. Officer & Director (Age 52)
  • Dr. Jonathan M. Young, Co-Founder, EVP & COO (Age 49)
  • Mr. Timothy Rolph, Co-Founder & Chief Scientific Officer (Age 65)
  • Mr. William R. White, EVP, CFO & Head of Corp. Devel. (Age 46)
  • Ms. Kitty Yale, Chief Devel. Officer (Age 47)

When did Akero Therapeutics IPO?

(AKRO) raised $75 million in an IPO on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

When does the company's lock-up period expire?

Akero Therapeutics' lock-up period expires on Tuesday, December 17th. Akero Therapeutics had issued 5,750,000 shares in its initial public offering on June 20th. The total size of the offering was $92,000,000 based on an initial share price of $16.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Cormorant Asset Management LP (2.84%), Janus Henderson Group PLC (2.81%), Janus Henderson Group PLC (2.81%), Hillhouse Capital Advisors LTD. (1.57%), Boxer Capital LLC (1.39%) and Hillhouse Capital Management LTD. (1.10%). Company insiders that own Akero Therapeutics stock include Aaron Royston, Global Strategic Fund I Venbio and Seth Loring Harrison. View Institutional Ownership Trends for Akero Therapeutics.

Which major investors are buying Akero Therapeutics stock?

AKRO stock was acquired by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Janus Henderson Group PLC, Janus Henderson Group PLC, Hillhouse Capital Advisors LTD., Boxer Capital LLC, Hillhouse Capital Management LTD., Rock Springs Capital Management LP and Price T Rowe Associates Inc. MD. Company insiders that have bought Akero Therapeutics stock in the last two years include Aaron Royston, Global Strategic Fund I Venbio and Seth Loring Harrison. View Insider Buying and Selling for Akero Therapeutics.

How do I buy shares of Akero Therapeutics?

Shares of AKRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Akero Therapeutics' stock price today?

One share of AKRO stock can currently be purchased for approximately $19.04.

How big of a company is Akero Therapeutics?

Akero Therapeutics has a market capitalization of $543.78 million. Akero Therapeutics employs 8 workers across the globe.View Additional Information About Akero Therapeutics.

What is Akero Therapeutics' official website?

The official website for Akero Therapeutics is http://www.akerotx.com/.

How can I contact Akero Therapeutics?

Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-487-6488.


MarketBeat Community Rating for Akero Therapeutics (NASDAQ AKRO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  14 (Vote Underperform)
Total Votes:  27
MarketBeat's community ratings are surveys of what our community members think about Akero Therapeutics and other stocks. Vote "Outperform" if you believe AKRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel